Stereotaxis (NYSEAMERICAN:STXS) Trading Down 5.3% – Here’s Why

Posted by Stanley Muller on Jun 7th, 2026

Stereotaxis Inc. (NYSEAMERICAN:STXS – Get Free Report)’s stock price fell 5.3% during trading on Friday . The company traded as low as $1.77 and last traded at $1.78. 590,981 shares traded hands during mid-day trading, an increase of 57% from the average session volume of 375,655 shares. The stock had previously closed at $1.88.

Wall Street Analyst Weigh In

STXS has been the subject of several recent research reports. Citigroup reissued a “market outperform” rating on shares of Stereotaxis in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $3.50 price objective (down from $4.00) on shares of Stereotaxis in a research note on Wednesday, May 13th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $3.88.

Get Our Latest Stock Report on Stereotaxis

Stereotaxis Trading Down 5.3%

The stock has a market cap of $173.98 million, a P/E ratio of -7.42 and a beta of 1.35. The firm’s fifty day moving average is $1.90 and its 200 day moving average is $2.14.

Stereotaxis (NYSEAMERICAN:STXS – Get Free Report) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). Stereotaxis had a negative return on equity of 163.30% and a negative net margin of 69.50%.The business had revenue of $8.64 million during the quarter, compared to analysts’ expectations of $9.24 million. Research analysts forecast that Stereotaxis Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Stereotaxis

Hedge funds have recently bought and sold shares of the stock. Moneta Group Investment Advisors LLC bought a new stake in shares of Stereotaxis in the third quarter valued at about $43,000. HRT Financial LP bought a new position in Stereotaxis in the fourth quarter worth $42,000. Schonfeld Strategic Advisors LLC boosted its stake in Stereotaxis by 47.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 17,801 shares of the company’s stock worth $41,000 after buying an additional 5,692 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Stereotaxis by 106.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after buying an additional 5,910 shares during the period. Finally, Sei Investments Co. raised its stake in shares of Stereotaxis by 108.9% in the 1st quarter. Sei Investments Co. now owns 518,884 shares of the company’s stock valued at $955,000 after buying an additional 270,443 shares in the last quarter. 45.35% of the stock is owned by institutional investors.

About Stereotaxis

(Get Free Report)

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.